Form 4: Roivant Sciences Director Vivek Ramaswamy Sells Over 1.1 Million Shares

Roivant Sciences Ltd. Director and 10% owner Vivek Ramaswamy reported the sale of over 1.1 million common shares in two separate transactions in mid-June 2025.

Summary

• Vivek Ramaswamy, a Director and 10% owner of Roivant Sciences Ltd. (ROIV), reported two significant sales of common shares.
• On June 18, 2025, Ramaswamy sold 565,266 common shares at a weighted average price of $11.45 per share, with prices ranging from $11.41 to $11.53.
• On June 20, 2025, an additional 577,007 common shares were sold at a weighted average price of $11.46 per share, with prices ranging from $11.45 to $11.54.
• Following these transactions, Ramaswamy directly holds 37,284,108 common shares and indirectly holds 13,357,857 common shares through a spousal account.
• The total number of shares sold across both transactions amounts to 1,142,273 common shares.

Sentiment

Score: 3

Explanation: The sale of over 1.1 million shares by a director and 10% owner is generally viewed negatively by the market, suggesting a potential lack of confidence or a belief that the shares are fully valued.

Negatives

• A significant sale of 1,142,273 common shares by a Director and 10% owner, Vivek Ramaswamy, which could be interpreted as a lack of confidence in the company's near-term prospects.
• The sales occurred at prices around $11.45-$11.46, indicating the insider chose to sell at these levels.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

Keywords

Roivant Sciences, ROIV, Vivek Ramaswamy, Insider Selling, Form 4, SEC Filing, Share Sale, Beneficial Ownership